Bladder cancer test kit UROCAN™

for kidney canceroncologyfor precision medicine

Urologic cancers are cancers of the urinary tract, including bladder cancer, renal (kidney) cancer and those specific to men, such as prostate cancer and testicular cancer. Prostate cancer is one of the most commonly diagnosed malignancies in men. The current treatment landscape for urologic cancers includes surgery, radiation therapy, chemotherapy and androgen deprivation therapy (ADT) for prostate cancer. Patients, however, often face recurrences and resistance to these treatments. Novel biomarkers help with prognosis of current treatments and development of targeted therapies and immunotherapies to improve therapeutic interventions. Targets 61 key genes in bladder and renal cancer Comprehensive testing of PDGFRA/B, c-KIT, RET receptor tyrosine kinase variants (amplification, point mutation and fusion) to guide targeted therapy Analyzes key genes in PI3K-mTOR and MAPK pathways Evaluates microsatellite instabilities (MSI) and mismatch repair deficiency (dMMR) to better inform immunotherapy decisions Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers Assesses genetic predisposition to cancers WHO IS IT FOR Urologic cancer patients seeking personalized medicine Urologic cancer patients with recurrent disease SAMPLE TYPES Tumor tissue (FFPE block/slides, or frozen tissue) Fine needle biopsy Liquid biopsy (plasma and others)